Daily non-political popular news in brief.

Keeping cancer at bay: Long-term therapy in the fight against multiple myeloma

There is no known cure for multiple myeloma, so its diagnosis means high-dose chemotherapy followed by repeated treatments with each relapse of the cancer -- a watch and wait approach. A new approach of providing patients with continuous therapy to keep the cancer at bay was explored by a team of international researchers from France, Switzerland and Belgium. Their findings will be published in the Nov. 15, 2006, issue of Blood.

Read more »

Keywords: keeping, cancer, bay, long-term, therapy, fight, multiple, myeloma, long, term

« Previous | Next »

Similar news on "Keeping cancer at bay: Long-term therapy in the fight against multiple myeloma":

1. 3-drug combination 'extremely promising' as first-line therapy for multiple myeloma
   12-11-2007 · EurekAlert!
   A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.
   Similar news · Read more »
   
2. Mayo Clinic -- Collaborating to move treatment research forward
   12-12-2006 · EurekAlert!
   Novel therapies are greatly improving the long-term outlook for patients with multiple myeloma, say researchers at Mayo Clinic Cancer Center, who have led efforts in testing these treatments and moving them quickly into first-line therapies.
   Similar news · Read more »
   
3. New therapeutic options for newly diagnosed multiple myeloma patients
   12-10-2007 · EurekAlert!
   Mayo Clinic researchers today presented results of a phase II trial of myeloma induction therapy -- a first step therapy designed to reduce cancer cells numbers -- with cyclophosphamide, bortezomib, and dexamethasone (Cybor-D) showing an improved response over the traditional lenalidomide-dexamethasone (L-Dex) therapy.
   Similar news · Read more »
   
4. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
   08-13-2007 · EurekAlert!
   Two new studies may lead to the development of more effective therapies for individuals with multiple myeloma, a common and incurable blood cell cancer. The research, published by Cell Press in the August issue of the journal Cancer Cell, provides new insight into the molecular mechanisms that underlie aberrant NF-κB activity in MM tumor cells and underscores the relevance of the signaling pathway as a target for MM therapy.
   Similar news · Read more »
   
5. Multiple myeloma clinical trial closes early
   04-04-2007 · EurekAlert!
   Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.
   Similar news · Read more »
   
6. Tiny Tampa Bay Fish Key To Evolution Of Immune System
   10-05-2006 · ScienceDaily
   A tiny fish offers insight into the human immune system, according to Florida researchers. The finding could lead to improved biodefense and better immune-boosting drugs to fight cancer and other disorders.
   Similar news · Read more »
   
7. Growth factor signals influence balance between normal growth and cancerous growth
   11-09-2006 · EurekAlert!
   Too much of a signaling protein called insulin-like growth factor-I (IGF-I) may fan the flames of cancer, while too little of the protein may cause short stature, dementia and osteoporosis. New research investigates how the growth hormone/IGF system is affected by the important tumor suppressor gene p53. This interplay of two signaling pathways reinforces questions about the long-term risks of prescribing growth hormone, while suggesting a future new avenue for cancer therapy.
   Similar news · Read more »
   
8. Gene knockouts reveal FoxOs' vital functions in cancer defense, health of stem cells
   01-25-2007 · EurekAlert!
   In an elegant, multiple-gene knockout experiment, a team of Boston scientists has discovered that a trio of molecules, called FoxOs, are fundamentally critical in preventing some cancers, maintaining blood vessel stability and in keeping blood-forming stem cells healthy.
   Similar news · Read more »
   
9. Drug combination slows progression of treatment resistant bone marrow cancer
   12-12-2006 · EurekAlert!
   Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.
   Similar news · Read more »
   
10. Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
    01-02-2008 · EurekAlert!
    Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years -- especially the development of bone metastases -- and increased survival in older men with potentially aggressive prostate cancer. This "neoadjuvant" hormonal therapy may allow men most at risk of developing bone metastases avoid long-term hormonal therapy later on.
    Similar news · Read more »